Autoimmune Pancreatitis: From Pathogenesis to Treatment

Area of Science:

• Gastroenterology
• Immunology
• Pathology

Background:

• Autoimmune pancreatitis (AIP) is a rare inflammatory condition affecting the pancreas.
• Diagnosis is challenging, requiring integrated clinical, radiological, serological, and pathological assessment.
• Two distinct subtypes, AIP type 1 (IgG4-related) and AIP type 2 (IgG4-negative), exhibit different underlying mechanisms.

Purpose of the Study:

• To elucidate the distinct pathogenic pathways of AIP types 1 and 2.
• To identify diagnostic tools that facilitate accurate disease identification.
• To explore novel therapeutic strategies for autoimmune pancreatitis and its relapses.

Main Methods:

• Comprehensive review of existing literature on AIP pathogenesis and treatment.
• Comparative analysis of the distinct pathophysiological features of AIP type 1 and type 2.
• Evaluation of current and emerging therapeutic modalities, including corticosteroids, immunomodulators, and biologics.

Main Results:

• AIP type 1 is associated with IgG4-related multiorgan disease, while AIP type 2 is pancreas-specific.
• Both types respond to corticosteroids, but distinct pathogenetic insights may guide targeted therapies.
• Rituximab and anti-TNF therapy show promise for relapsing or steroid-dependent cases, offering alternatives to traditional immunosuppressants.

Conclusions:

• Understanding the separate pathogenesis of AIP types 1 and 2 is crucial for accurate diagnosis and tailored treatment.
• Biologic therapies represent a promising avenue for managing refractory or relapsing autoimmune pancreatitis, potentially mitigating side effects of long-term immunosuppression.